You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Glenmark Pharma gains after USFDA approval

Capital Market 

Pharmaceuticals rose 2.32% to Rs 645 at 11:09 IST on BSE after the company said it received abbreviated new drug application approval for clindamycin and gel.

The announcement was made during trading hours today, 15 March 2019.

Meanwhile, the S&P BSE Sensex was up 245.07 points, or 0.65% to 37,999.96.

On the BSE, 26,000 shares were traded in the counter so far compared with average daily volumes of 1.51 lakh shares in the past two weeks. The stock had hit a high of Rs 651.50 and a low of Rs 634.80 so far during the day. The stock hit a 52-week high of Rs 711.55 on 10 September 2018. The stock hit a 52-week low of Rs 483.60 on 30 May 2018.

Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the Food & Drug Administration (USFDA) for clindamycin and gel, 1% / 5%, a generic version of Gel, 1% / 5%, of Valeant Bermuda.

According to IQVIA sales data for the 12 month period ending January 2019, the Gel, 1% / 5% market achieved annual sales of approximately $99.4 million.

Glenmark's current portfolio consists of 151 products authorized for distribution in the US marketplace and 53 ANDA's pending approval with the In addition to these internal filings, continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

On a consolidated basis, Glenmark Pharmaceuticals' net profit rose 11.08% to Rs 116.34 crore on 15.58% increase in net sales to Rs 2509.78 crore in Q3 December 2018 over Q3 December 2017.

Glenmark Pharmaceuticals (GPL) is a research-driven, global,

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, March 15 2019. 11:07 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU